In a randomized crossover trial, glymphatic clearance during normal sleep increased morning plasma levels of AD biomarkers compared to sleep deprivation, supporting a key role for glymphatic function in AD pathophysiology.
Key Findings
Results
Normal sleep increased morning plasma levels of Alzheimer's disease biomarkers compared to sleep deprivation, indicating glymphatic clearance of amyloid beta and tau from brain to plasma in humans.
Study used a randomized crossover trial design with 39 participants
Participants underwent overnight monitoring using an investigational device that measured dynamic changes in synaptic-metabolic release and glymphatic activity
Plasma AD biomarker levels were higher in the morning following normal sleep versus sleep deprivation
The crossover design allowed each participant to serve as their own control across sleep and sleep deprivation conditions
Results
Sleep-active physiological processes, particularly reduced brain parenchymal resistance, enhance overnight glymphatic clearance of AD biomarkers to plasma.
The investigational device measured dynamic changes in synaptic-metabolic release and glymphatic activity
Reduced brain parenchymal resistance was identified as a key mechanism facilitating glymphatic clearance during sleep
The findings mirror predictions from a multicompartment model based on published data on amyloid beta and tau release and clearance
These sleep-active processes were distinguished from waking-state glymphatic function
Results
Observed changes in plasma AD biomarkers during sleep mirrored predictions from a multicompartment computational model of amyloid beta and tau dynamics.
A multicompartment model was constructed based on published data on amyloid beta and tau release and clearance
The model predicted the direction and pattern of plasma biomarker changes associated with glymphatic clearance during sleep
Concordance between observed data and model predictions strengthened the mechanistic interpretation of results
The model incorporated known kinetics of AD biomarker production and elimination across brain compartments
Background
Glymphatic impairment has been proposed as a mechanistic link between sleep disruption and Alzheimer's disease, with animal models showing that glymphatic impairment alone can drive AD pathology.
Prior to this study, whether the glymphatic system clears amyloid beta and tau in humans remained unknown
Dysfunction of the glymphatic system had been proposed as a mechanistic link between sleep disruption and AD
Animal model evidence established that glymphatic impairment alone can drive AD pathology
This trial represents a direct human test of glymphatic clearance of AD biomarkers
Conclusions
Enhancement of the glymphatic system is suggested as a potential therapeutic strategy to slow Alzheimer's disease progression.
Results support a key role for glymphatic function in AD pathophysiology
The authors suggest glymphatic enhancement as a potential therapeutic strategy
The proposed goal of such a strategy would be to slow disease progression
Sleep-active physiological processes represent a modifiable target for intervention
What This Means
This research suggests that the brain's waste-clearance system — called the glymphatic system — actively flushes out proteins linked to Alzheimer's disease (amyloid beta and tau) during sleep, moving them from the brain into the bloodstream. In a carefully designed study where 39 people each experienced both a normal night of sleep and a night of sleep deprivation (in randomized order), researchers found that blood levels of these Alzheimer's-related proteins were higher in the morning after normal sleep than after staying awake all night. This is consistent with the idea that sleep is when the brain 'takes out the trash,' and that missing sleep reduces this cleaning process.
The researchers also used a special monitoring device to track brain activity related to the glymphatic system overnight, and they built a mathematical model to predict what the blood levels of these proteins should look like if the glymphatic system was working as expected. The real data closely matched those predictions, strengthening the case that the glymphatic system is genuinely responsible for clearing these proteins in humans — not just in animals as had previously been shown.
This matters because the accumulation of amyloid beta and tau in the brain is central to Alzheimer's disease, and chronic sleep disruption is a known risk factor for the condition. This research suggests that the link between poor sleep and Alzheimer's may work, at least in part, through a less efficient glymphatic system. It also raises the possibility that treatments or behaviors that improve glymphatic function during sleep — potentially including improving sleep quality — could one day help slow the development of Alzheimer's disease.
Dagum P, Elbert D, Giovangrandi L, Singh T, Venkatesh V, Corbellini A, et al.. (2026). The glymphatic system clears amyloid beta and tau from brain to plasma in humans.. Nature communications. https://doi.org/10.1038/s41467-026-68374-8